Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 146,541 - 146,560 results of 232,109 for search '(( 5 ((step decrease) OR (we decrease)) ) OR ( 10 ((mean decrease) OR (a decrease)) ))', query time: 2.49s Refine Results
  1. 146541
    Video2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4

    Video2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  2. 146542
    Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  3. 146543
    Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4

    Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  4. 146544
    Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  5. 146545
    Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4

    Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  6. 146546
    Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  7. 146547
    Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  8. 146548
    Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  9. 146549
    Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4

    Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  10. 146550
    Table1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.DOCX

    Table1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.DOCX by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  11. 146551
    Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4

    Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  12. 146552
    Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  13. 146553
    Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  14. 146554
    Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF

    Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  15. 146555
    Table1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.DOCX

    Table1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.DOCX by Kai Wang (21246)

    Published 2023
    “…We found that chronic mavacamten treatment of R403Q ECTs: (i) shortened relaxation time, (ii) reduced APD<sub>90</sub> prolongation, (iii) upregulated ADRB2, ATP2A2, RYR2, and CACNA1C, (iv) decreased B-type natriuretic peptide (BNP) mRNA and protein expression levels, and (v) increased sarcomere length and reduced sarcomere disarray.…”
    Save to List
    Saved in:
  16. 146556
    Fibrotic changes in the murine lungs and livers of the DMSO, valsartan, and PD123319 groups.

    Fibrotic changes in the murine lungs and livers of the DMSO, valsartan, and PD123319 groups. by Saori Yaguchi (418831)

    Published 2013
    Save to List
    Saved in:
  17. 146557
    Genes encoding kinases in the InsP biosynthesis pathway are required for wild-type filamentous growth.

    Genes encoding kinases in the InsP biosynthesis pathway are required for wild-type filamentous growth. by Kaitlyn L. Norman (811034)

    Published 2018
    “…Measurements indicate the mean and standard deviation of three replicates; measurements for each replicate are provided in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1007493#pgen.1007493.s009" target="_blank">S5 Table</a>. …”
    Save to List
    Saved in:
  18. 146558
    Genome-wide miRNA response to anacardic acid in breast cancer cells

    Genome-wide miRNA response to anacardic acid in breast cancer cells by David J. Schultz (4423906)

    Published 2017
    “…Anacardic acid (AnAc) is a dietary phenolic lipid that inhibits both MCF-7 estrogen receptor α (ERα) positive and MDA-MB-231 triple negative breast cancer (TNBC) cell proliferation with IC<sub>50</sub>s of 13.5 and 35 μM, respectively. To identify potential mediators of AnAc action in breast cancer, we profiled the genome-wide microRNA transcriptome (microRNAome) in these two cell lines altered by the AnAc 24:1n5 congener. …”
    Save to List
    Saved in:
  19. 146559
    SEAwise report on the effects of fishing on food webs and community diversity aimed at populating the MSFD Descriptor 4 and based on food web and end-to-end modelling.

    SEAwise report on the effects of fishing on food webs and community diversity aimed at populating the MSFD Descriptor 4 and based on food web and end-to-end modelling. by Robert Thorpe (9207203)

    Published 2024
    Save to List
    Saved in:
  20. 146560
    AntagomiR-365 inhibits tumorgenesis and restores NFIB expression both <i>in vitro</i> and <i>in vivo</i>.

    AntagomiR-365 inhibits tumorgenesis and restores NFIB expression both <i>in vitro</i> and <i>in vivo</i>. by Meijuan Zhou (581065)

    Published 2014
    “…Relative tumor volumes are shown with respect to day 7. Data are plotted as mean ± S.E. (D) AntagomiR-365 injection drastically decreased the expression levels of the miR-365 in xenografts and thus led to the up-regulation of NFIB and p53 and down-regulation of CDK6 and Bcl-2. …”
    Save to List
    Saved in:

Search Tools: